Irritable Bowel Syndrome (IBS) is a common problem facing gastroenterologists and primary care physicians, its prevalence ranged between 10 to 20 % of the population worldwide .
Ahmed et al., 2022 reported that using fecal microbiota transplant (FMT) as a method of treatment of IBS is an effective choice and they published an article in the current issue of the Afro-Egypt J Infect Endem Dis  with the title "Effect of Fecal Microbiota Transplant versus Conventional Medications in Treatment of Irritable Bowel Syndrome".  The study included 30 patients with IBS symptoms, patients classified into three groups: group A: healthy donors, group B: patients who received Mebeverine and Simethicone and group C: patients who managed by FMT.  
Overall the study opened the gate for further studies that meticulously investigate FMT as regards donor selection criteria, stool dose, and route of administration, using more objective parameters such the effective bacterial signature or microbiome diversity, hoping to reach future safe, selective and effective FMT.